• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Outcomes with lower intensity therapy in TP53-mutated acute myeloid leukemia.

作者信息

Boddu Prajwal, Kantarjian Hagop, Ravandi Farhad, Garcia-Manero Guillermo, Borthakur Gautam, Andreeff Michael, Jabbour Elias J, Benton Christopher B, DiNardo Courtney D, Konopleva Marina, Daver Naval, Patel Keyur, Takahashi Koichi, Kanagal-Shamanna Rashmi, Cortes Jorge, Kadia Tapan

机构信息

a Department of Leukemia , The University of Texas, M. D. Anderson Cancer Center , Houston , TX , USA.

出版信息

Leuk Lymphoma. 2018 Sep;59(9):2238-2241. doi: 10.1080/10428194.2017.1422864. Epub 2018 Jan 17.

DOI:10.1080/10428194.2017.1422864
PMID:29338567
Abstract
摘要

相似文献

1
Outcomes with lower intensity therapy in TP53-mutated acute myeloid leukemia.TP53 突变型急性髓系白血病采用低强度治疗的结果。
Leuk Lymphoma. 2018 Sep;59(9):2238-2241. doi: 10.1080/10428194.2017.1422864. Epub 2018 Jan 17.
2
Phase 1 study of epigenetic priming with decitabine prior to standard induction chemotherapy for patients with AML.表观遗传学诱导预处理联合标准诱导化疗治疗 AML 患者的 1 期临床研究。
Blood. 2011 Aug 11;118(6):1472-80. doi: 10.1182/blood-2010-11-320093. Epub 2011 May 25.
3
Combination of cladribine and cytarabine is effective for childhood acute myeloid leukemia: results of the St Jude AML97 trial.克拉屈滨与阿糖胞苷联合用药对儿童急性髓系白血病有效：圣犹大AML97试验结果
Leukemia. 2009 Aug;23(8):1410-6. doi: 10.1038/leu.2009.30. Epub 2009 Feb 26.
4
Induction chemotherapy for acute myelogenous leukemia.急性髓性白血病的诱导化疗。
Curr Hematol Rep. 2005 Jan;4(1):49-50.
5
Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia.序贯阿扎胞苷联合来那度胺治疗未经治疗的老年急性髓系白血病。
Haematologica. 2013 Apr;98(4):591-6. doi: 10.3324/haematol.2012.076414. Epub 2012 Dec 14.
6
Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial.克拉屈滨与小剂量阿糖胞苷交替联合地西他滨作为老年急性髓系白血病患者的一线治疗：一项2期单臂试验
Lancet Haematol. 2018 Sep;5(9):e411-e421. doi: 10.1016/S2352-3026(18)30132-7. Epub 2018 Aug 13.
7
TP53 immunohistochemistry correlates with mutation status and clearance in decitabine-treated patients with myeloid malignancies.TP53免疫组化与地西他滨治疗的髓系恶性肿瘤患者的突变状态及清除情况相关。
Haematologica. 2019 Aug;104(8):e345-e348. doi: 10.3324/haematol.2018.205302. Epub 2019 Feb 21.
8
Epigenetic priming with decitabine followed by low-dose idarubicin/cytarabine has an increased anti-leukemic effect compared to traditional chemotherapy in high-risk myeloid neoplasms.与传统化疗相比，在高危骨髓肿瘤中，先用地西他滨进行表观遗传启动，再给予低剂量伊达比星/阿糖胞苷，具有增强的抗白血病作用。
Leuk Lymphoma. 2016;57(6):1311-8. doi: 10.3109/10428194.2015.1091931. Epub 2015 Oct 13.
9
Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia.表观遗传学治疗与强化化疗在新诊断的老年急性髓系白血病患者中的生存相似。
Blood. 2012 Dec 6;120(24):4840-5. doi: 10.1182/blood-2012-06-436055. Epub 2012 Oct 15.
10
Efficacy and Toxicity of Induction Therapy with Cladribine, Idarubicin, and Cytarabine (IAC) for Acute Myeloid Leukemia.克拉屈滨、伊达比星和阿糖胞苷（IAC）诱导治疗急性髓系白血病的疗效与毒性
Anticancer Res. 2017 Feb;37(2):713-717. doi: 10.21873/anticanres.11368.

引用本文的文献

1
Fitness assessment in acute myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet.急性髓系白血病的体能评估：代表欧洲白血病网的专家小组建议
Blood Adv. 2025 May 13;9(9):2207-2220. doi: 10.1182/bloodadvances.2024013744.
2
Transplant options and outcomes for TP53 myeloid disease.TP53髓系疾病的移植选择与结果
Hematology Am Soc Hematol Educ Program. 2024 Dec 6;2024(1):335-339. doi: 10.1182/hematology.2024000558.
3
Therapy-Related Myeloid Neoplasm: Biology and Mechanistic Aspects of Malignant Progression.
治疗相关的髓系肿瘤：恶性进展的生物学和机制方面
Biomedicines. 2024 May 10;12(5):1054. doi: 10.3390/biomedicines12051054.
4
Unmet Horizons: Assessing the Challenges in the Treatment of -Mutated Acute Myeloid Leukemia.未被触及的前沿：评估治疗FLT3突变型急性髓系白血病的挑战
J Clin Med. 2024 Feb 14;13(4):1082. doi: 10.3390/jcm13041082.
5
Single-center phase 2 study of PD-1 inhibitor combined with DNA hypomethylation agent + CAG regimen in patients with relapsed/refractory acute myeloid leukemia.单中心 PD-1 抑制剂联合 DNA 低甲基化剂+ CAG 方案治疗复发/难治性急性髓系白血病的 2 期临床研究。
Cancer Immunol Immunother. 2023 Aug;72(8):2769-2782. doi: 10.1007/s00262-023-03454-y. Epub 2023 May 11.
6
Optimizing outcomes in secondary AML.优化继发性 AML 的治疗效果。
Hematology Am Soc Hematol Educ Program. 2022 Dec 9;2022(1):23-29. doi: 10.1182/hematology.2022000324.
7
TP53-Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Biology, Current Therapy, and Future Directions.TP53 突变型骨髓增生异常综合征和急性髓系白血病：生物学、当前治疗和未来方向。
Cancer Discov. 2022 Nov 2;12(11):2516-2529. doi: 10.1158/2159-8290.CD-22-0332.
8
How I Treat -Mutated Acute Myeloid Leukemia and Myelodysplastic Syndromes.我如何治疗突变型急性髓系白血病和骨髓增生异常综合征。
Cancers (Basel). 2022 Sep 18;14(18):4519. doi: 10.3390/cancers14184519.
9
Are We Moving the Needle for Patients with -Mutated Acute Myeloid Leukemia?我们是否正在为携带 - 突变的急性髓系白血病患者带来改变？
Cancers (Basel). 2022 May 14;14(10):2434. doi: 10.3390/cancers14102434.
10
Evolution of Therapy for Older Patients With Acute Myeloid Leukemia: How Should We Use Currently Available Agents?老年急性髓系白血病患者治疗的演变：我们应如何使用现有药物？
Cancer J. 2022;28(1):67-72. doi: 10.1097/PPO.0000000000000574.